đŖ In June 2021, Novartis International AG announced receiving approval from the US Food & Drug Administration (FDA) for the Breakthrough Therapy Designation (BTD) to 177Lu-PSMA-617 in patients with conditions of metastatic castration-resistant prostate cancer (mCRPC).
âļī¸ đđĸđđ° đ
đŽđĨđĨ đđđŠđ¨đĢđ đ°đĸđđĄ đđđđđŦđ đđ§đŦđĸđ đĄđđŦ:- https://www.marknteladvisors.c....om/research-library/
#prostate_cancer_market #prostatecancer #cancer #biopharma #ultrasound #tumor #healthcare #marknteladvisors #marketresearch
